Seaport Therapeutics, Inc. (NASDAQ:SPTX – Free Report) – Investment analysts at HC Wainwright boosted their FY2026 earnings estimates for Seaport Therapeutics in a report issued on Wednesday, November 4th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($3.95) per share for the year, up from their previous forecast of ($4.09). HC Wainwright currently has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Seaport Therapeutics’ current full-year earnings is ($4.39) per share. HC Wainwright also issued estimates for Seaport Therapeutics’ Q4 2026 earnings at ($0.53) EPS, Q1 2027 earnings at ($0.61) EPS, Q3 2027 earnings at ($0.69) EPS, Q4 2027 earnings at ($0.71) EPS and FY2027 earnings at ($2.65) EPS.
Other equities analysts also recently issued reports about the company. UBS Group restated a “buy” rating on shares of Seaport Therapeutics in a research report on Thursday, October 8th. JonesTrading began coverage on Seaport Therapeutics in a research note on Wednesday, August 26th. They issued a “buy” rating and a $32.00 price objective on the stock. Canaccord Genuity Group assumed coverage on Seaport Therapeutics in a report on Wednesday, October 14th. They issued a “buy” rating and a $28.00 target price on the stock. Seaport Research Partners set a $28.00 target price on shares of Seaport Therapeutics in a research report on Wednesday, October 14th. Finally, JPMorgan Chase & Co. raised their price target on shares of Seaport Therapeutics from $40.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.12.
Read Our Latest Analysis on Seaport Therapeutics
Seaport Therapeutics Stock Performance
NASDAQ SPTX opened at $20.39 on Friday. The company has a 50-day moving average of $20.77. Seaport Therapeutics has a 12 month low of $14.85 and a 12 month high of $28.38.
Seaport Therapeutics (NASDAQ:SPTX – Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.09.
Insider Buying and Selling at Seaport Therapeutics
In other Seaport Therapeutics news, Director Denice Torres acquired 5,000 shares of the company’s stock in a transaction dated Tuesday, November 3rd. The shares were bought at an average cost of $19.86 per share, with a total value of $99,300.00. Following the purchase, the director directly owned 5,000 shares of the company’s stock, valued at $99,300. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Institutional Investors Weigh In On Seaport Therapeutics
Large investors have recently added to or reduced their stakes in the business. Alps Advisors Inc. increased its holdings in Seaport Therapeutics by 30.5% in the third quarter. Alps Advisors Inc. now owns 70,921 shares of the company’s stock worth $1,430,000 after purchasing an additional 16,593 shares in the last quarter. HighTower Advisors LLC acquired a new position in Seaport Therapeutics in the second quarter valued at approximately $362,000. Squarepoint Ops LLC acquired a new position in Seaport Therapeutics in the second quarter valued at approximately $538,000. State Street Corp acquired a new position in Seaport Therapeutics in the second quarter valued at approximately $1,448,000. Finally, Alyeska Investment Group L.P. bought a new position in shares of Seaport Therapeutics during the 2nd quarter worth approximately $1,629,000.
Seaport Therapeutics Company Profile
Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for central nervous system (CNS) disorders. The company uses its Glyph platform, a technology designed to create prodrugs that may improve the delivery, tolerability, and effectiveness of certain therapies, including treatments intended to reach the brain.
Seaport’s pipeline includes investigational therapies for neurological and neuropsychiatric conditions. Its programs have included GTX-102, an oral investigational medicine being developed for Angelman syndrome, a rare genetic neurodevelopmental disorder, as well as additional candidates aimed at addressing unmet needs in CNS care.
The company was established with support from PureTech Health and is headquartered in Boston, Massachusetts.
Read More
- Five stocks we like better than Seaport Therapeutics
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Seaport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seaport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
